Helping Ourselves & Others We Love With Diabetes

Adapted by Paul Madden

Initially Developed by my Colleague, Friend, Tom Boyer, Leading Advocacy Expert,

Director, State Government Affairs; NovoNordisk

Advocacy

• To share:• some helpful information, • define the stakeholders, • raise some thoughts/questions for your discussion and consideration,

• if needed, inflame your passions in advocacy to benefit people living with diabetes.

Thoughts About My Presentation

Who amongst us …

• Knows the name of the President, the VP• Knows the name of their Member of Congress and Senators• Has met with their Member of Congress to further a goal• Votes• Writes letters or email to elected officials• Or … has an opinion about anything

If you answered yes to any of these questions then … YOU ARE AN ADVOCATE, THANK YOU!

I assume you are all here because you believe there is much more that we have to do. We need more determined advocates who understand the challenges, are humble enough to develop the solutions together, and stay focused so we can all, YES ALL; Type 1, Type 2, Gestational, Type 3, Pre-Diabetes

can lead healthier, more productive, happier lives!

A Poll of the Room

• Stakeholders 1: People Living with Type 1, 2, and 3 diabetes, Gestational Diabetes.

• Stakeholders 2: Governments, Businesses, Schools, Taxpayers (our acquaintances, our friends), etc…

• Without being inclusive with Stakeholders 1 and 2 we will not secure the growing number of advocates needed to ensure that access to optimal health and life’s robust opportunities (no discrimination) are realized by people living with diabetes and at risk of developing diabetes.

Stakeholders

Question; How Much Do I (YOU) Value Diabetes Health and the Health of My Country?

They are connected.

If you value:•optimal health, for you, your loved ones, friends, co-workers, •a productive country that supports its people with proper access to care •the long term reduction of manageable health care costs which are shared by all. Now let me share just a glimpse of DM in the US, what has occurred to date, what works and what doesn’t and how our focused efforts can build a bolder story of success for people living with diabetes for today and our many tomorrows.

Age-Adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S. Adults Aged 18

Years or older

1994 2000

No Data <4.5% 4.5-5.9% 6.0-7.4% 7.5-8.9% >9.0%

Source: CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics

2010

Diabetes, a Growing Epidemic

- 29 million people in the United States have diabetes, CDC 2 - estimated 86 million Americans

Costs of Diagnosed Diabetes $245 billion in 2012

1 in 10 health care dollars in the U.S. are spent directly on diabetes and its complications,

1 in 5 health care dollars in the U.S. goes to the care of people with diagnosed diabetes.

People with diabetes who do not have health insurance: have 79% fewer physician office visits,* are prescribed 68% fewer medications than people with

insurance coverage* have 55% more emergency department visits than people

who have insurance*

The U.S. and much of the world are in dire financial straits. Leaders must understand that balanced diabetes as well as delayed, prevented and screened earlier Type 2 diabetes increases productivity in all parts of life, improves the quality of life and significantly decreases health care costs. Money Talks.

Diabetes has the Largest % Increase inCause of Death from 2010 to 2011

According to the CDC, among chronic diseases, diabetes saw the biggest increase in death rate from 2010 to 2011; rising 3.4%.  In comparison, death rates from heart disease, cancer and stroke dropped. 

Source: Hoyert DL and Xu J. Deaths: Preliminary Data for 2011. National Vital Statistics Report. 61(6): October 10, 2012; To access the full National Vital Statistics Report, visit http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf

Top 10 Causes of Death in the U.S. (% change from 2010 to 2011)

•Heart disease (-3%)•Cancer (-2.4%)•Chronic lower respiratory diseases (+1.2%)•Stroke (-3.1%)•Accidents or unintentional injuries (unchanged)•Alzheimer’s disease (-2%)•Diabetes (+3.4%)•Influenza and pneumonia (+4%)•Kidney-related diseases (-12.4%)•Suicide (-0.8%)

Diabetes; State & Federal How are we doing?

• Spotty coverage of insulin pumps and continuous glucose monitoring by federal health and insurers

• Glucose testing strips more often limited by Medicaid, Medicare and some private insurers. Insurers telling ill informed doctors what to prescribe.

• 4 year delay in the CA Supreme Court hearing a discrimination case impacting school-children with diabetes

• >27% of the Seniors have diabetes. Insulin Pumps and CGMs not specifically covered by Medicare. Often pay for just 2 blood strips per day. (This inadequate coverage suggests that our diabetes get easier to balance as we get older?? We wish this was true. Often >more hypoglycemic unawareness, greater risk of more serious complications of hypoglycemia…)

Diabetes Action Plan (Kentucky/Texas Model)

Requires collaboration among several State Agencies to collaborate to identify goals and benchmarks while also developing individual entity plans to reduce the incidence of diabetes in Kentucky, improve diabetes care, and control complications associated with diabetes.

Recent Challenges that became wins: Diabetes Special School, Sharps containers…

Best Practice:Pass Targeted Legislation

Other Diabetes Legislation: Safety for Students with Diabetes (Georgia Model)With parental consent, grants students the autonomy to self-manage and self-treat their diabetes AND trains school personnel in diabetes care. Covered Diabetes Benefits for State Medicaid Recipients Recommended covered benefits include: Mandatory screening for gestational diabetes, participation in NIH, evidence-based Diabetes Prevention Program

“For the first time state agencies are talking about how we can collectively tackle the diabetes epidemic in Kentucky.”

- Dr. Steve Davis, Director, KY Department of Public Health

Corporate Commitment to Access = •Social Responsibility, •Selling Products/Services AND YES We Need and Want Them to Sell Good Products!

Right partnerships are the key to success

At this very moment, your Congressperson is thinking about…A. Whether the move

to defeat the previous question will succeed and defeat the rule for today’s scheduled legislation.

B. Today’s hometown news interview

C. The needs of people with diabetes

D. Re-election

At this very moment, your Congressperson is most probably thinking about…

Re-election

About how many meetings will a Congressperson have on the average day?

23-30 meetings/day

If the Congressional staffer you meet is so young that you think he or she is cutting class…

Deal with it. Congress is run by people a large number of people. Respect and work closely with them.

Congressional staff love to get…

One concise page with local contact information (e.g. business card) attached.

After you meet an elected official, assume that the official visited…

Has forgotten that you even exist.

If you follow-up, you’ll get what you want 90% of the time.

• Make notes of requested information

• Secure business cards for follow-up conversations

• Do debrief as instructed

• Send email thank yous

• Reminder call/email after 30 days –

• Outlook 90 day reminder• Find other people who

can support you and bring the same issue up with the legislator

Short Term Follow-up Long Term Follow-up

In Advocacy, Remember, At the End of the Day

At the end of the day governments, businesses and the general public vote mainly with their wallets in mind; what supports a better standard of life, their life opportunities, and again their wallets. The productivity advantages of balanced, earlier diagnosed, and delayed and prevented diabetes must be stressed and captured in programs.Balanced diabetes and diabetes that is prevented or significantly delayed costs society 10X to 30X less than consistently unbalanced diabetes with serious complications. Your passion, ample knowledge on diabetes advocacy, your network all woven together will make a significant difference in life outcomes for all of us.Thank you!

• Commit to monitor for problems related to discrimination and health coverage for people with diabetes in your community, in your schools, at your business, on your daughter’s sports team?

• Commit to responding to advocacy alerts generated by reputable organizations?

• Commit to develop a strong Diabetes Advocacy presence in your community, in your state and/or on the Federal level?

• Work with other diabetes advocates with humility.

How You Can Help

“There are risks and costs to a program of action, but they are far less than the long-range costs of comfortable inaction.” -John F. Kennedy

If you don’t stretch your limits, You set your limits.

No One Can Advocate Alone

•What are YOU angry about relative to your diabetes or loved one’s diabetes?•Are you ready to you engage in the advocacy effort to help fight diabetes and improve the lives of people impacted by the diabetes of all types?•Are you ready to bring other friends and leaders along to join you?

WE NEED YOU!!!WE WANT YOU BECAUSE YOU ARE DETERMINED

AND YOU CARE

“There are only two ways to live your life. One is as though nothing is a miracle. The other is as though everything is a miracle. Albert Einstein.

Let’s you and I make some miracles to benefit people with diabetes!

The Role of FDA in regulating DiabetesDevices and Advancing Safe Innovation in

the Management of Diabetes

Diabetes Advocacy MasterLabJuly 2, 2014

Stayce Beck, Ph.D., M.P.H.Office of In Vitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health/FDAStayce.beck@fda.hhs.gov

Agenda

• General introduction to FDA• How does FDA regulate Glucose

Meters?

• Diabetes Diagnostic Devices: Where are we now?

Diabetes• People with diabetes face many challenges:

– Immediate risks everyday due to potential for severe hypo- and hyperglycemia

– Long-term heath risks due to glycemic variability and hyperglycemia• Quality of life challenges

– The need for multiple devices (meters, pumps, insulin pens, lancets, etc…)

– Pain at lancing and injection sites– Complicated drug dosing and nutrition decisions– Data overload can be frustrating (e.g., CGM data)

• Needs:– Devices that improve lives without adding complexity– Simple, easy to interpret device data outputs– Easy to use, safe, and effective medical products

Center for Devices and Radiological Health

Center for Drug Evaluation and Research

Center for Veterinary Medicine

Center for Biologic Evaluation and Research

Center for Food Safety and Applied Nutrition

Office of Regulatory Affairs

FDA

Center for Tobacco

Protect and Promote Public Health

Who Are We?• Center for Devices and Radiological Health/ Office of In Vitro Diagnostics

and Radiation (OIR)• Division of Chemistry and Toxicology Devices: Courtney Lias, Ph.D.,

Director• Diabetes Diagnostic Devices Branch: Stayce Beck, Branch Chief• 44 staff and managers in the Division• Approximately 40-45% of Division work is directly Diabetes-related

– Blood Glucose Meters– Point-of-Care glucose analyzers– Central Laboratory analyzers– Blood gas analyzers– HbA1c tests– Continuous Glucose Monitoring Systems (CGMs)– Artificial Pancreas Systems

• Other Divisions – insulin pumps (not CGM-enabled), insulin pens, lancets, etc.

Risk-Based Classification of IVDs:

• The classification of an IVD is risk-based, and determined based upon the intended use of the device

• The risk of an IVD is based on the consequences of a false result

• Three Classification levels– Class I: common, low risk devices– Class II: more complex, moderate risk– Class III: most complex, high risk and novel

intended uses

Premarket Notification: 510(k)• 510(k) submission required of most class II devices• Submission has 90 day review clock• FDA clearance based on “substantial equivalence” to

legally marketed device (predicate device)• What substantial equivalence to predicate device means:

– Similar intended use – Similar performance characteristics– Similar fundamental scientific technology

• What substantial equivalence may not mean– Identical technology

• Submissions may require clinical data• Summary of FDA’s review and basis for decision is

posted on the FDA website

Premarket Application (PMA)• 180 day review clock• Demonstration of safety and effectiveness• Does not use predicates• Submissions often include clinical data• Pre-approval inspection performed• FDA may seek advisory panel decision prior to

approval• Summary of Safety and Effectiveness Data (SSED)

posted publicly on web

Premarket Review

• Assessing Safety – Risk of misdiagnosis due to a false positive or

false negative result– Assessing warnings against unsafe use

• Demonstrating Effectiveness– Assessing device performance characteristics– Directions and conditions for use

Analytical Validity

• Repeatability/Reproducibility– Will I get the same result in repeated tests over time?– Will I get the same result as someone else testing the

same sample?• Accuracy

– Will I get results that are the same as “Truth”?– “Truth” – may be a reference method, clinical endpoint,

predicate device, etc.

Example: Blood Glucose Meter

Blood Glucose Meter: Analytical Performance

• Precision• Measurement Range• Accuracy: Percent of Readings within 5, 10, 15 % of

reference- example 95% w/in 15%, 100% w/in 20% \• Interference• Hematocrit• Altitude• Temperature

• Clinical Validity– Device must have a clinical indication– Device should add value to clinical

management• Clinical Validity claims may be based on:

- Existing clinical data (i.e. no new clinical data needed)

- New clinical trial data- Review of information in the literature- Current clinical knowledge

Clinical Performance

Over the CounterIVDs for consumer use (OTC) have additional requirements:

• Data submitted to demonstrate that the tests are accurate in the hands of lay users (including sample collection)

• Studies are performed to evaluate how well lay users can understand the instructions without prompting, perform a self-test (or collect a sample), and obtain an accurate result

• Lay users’ ability to understand the results of the test are also evaluated

• Human factors are also considered in the review, where applicable

Medical Device Reports (MDRs)• Reports to FDA by user facility/manufacturer when a

device:– Caused or contributed, or may have caused or may have

contributed to a death– Caused or contributed, or may have caused or may have

contributed to a serious injury– Malfunctioned or failed to meet specifications

(manufacturer only): Recurrence could result in death or serious injury

• Required timeframe for reporting– 5-30 days, depending on severity– Follow-ups when needed

• FDA assesses reports and decides if action is needed• Anyone can report! We have a smart phone app!

Diabetes Diagnostic Devices: Where are we now?

Glucose Meters• Improvements in consumer features over the last few years

• Improvements in interference detection

• FDA published two draft blood glucose meter guidances in January 2014

Guidance Process:

• Solicit input from Stakeholders • Use input to draft guidance• Release draft guidance to the public- not enforceable!!!• Solicit feedback from the community on the draft guidance with

comments to the docket• Review the comments to the docket, revise the guidance

accordingly• Discuss the feedback with stakeholders• Revise the guidance based on the feedback• Release final guidance to the public

Draft Glucose Meter Guidances• Increased Accuracy • Accuracy of meter on the outside of the box• Studies to make sure meter works in different environments• Draft documents can be found at: Regulations.gov• We received over 600 comments, with over 200 from people with diabetes

or their family members. We specifically asked that people comment on:• Things they didn’t like and suggestions of things that they would like to

see along with their comment• If something wasn’t clear, so we could clarify it• Things they liked so we can have a balanced picture of feedback from all

stakeholders

Post Market Safety• >25,000 Medical Device Reports/year for blood glucose meters

• Variability in quality of reporting, decision-making at firms

• Challenges:– High volume of data– Low quality data– Inconsistent compliance

• Solutions– New methods for data analysis– Developing guidance for manufacturers

• Clarify reporting criteria/methodology• Increase consistency across manufacturers

– Potential new surveillance program?

Continuous Glucose Meters• CGMs are home use devices that continuously measure glucose in interstitial

fluid

• Have demonstrated benefit for the patients that use them

• Recent Approvals– DexCom G4, down to 2 years of age!– Medtronic Enlite (part of 530G system)

• Challenges remain:– Sensor accuracy needs improvement– New materials/technologies to reduce sensor biofouling needed– Improved reliability needed (e.g., signal dropout)– Better standards would help advance technology

Artificial Pancreas• Challenges:

– Many still struggle to maintain good glycemic control– Hypoglycemic unaware individuals at risk– Risk of nighttime hypoglycemia– Better quality of life needed

• The development of an Artificial Pancreas will improve outcomes for people with diabetes

• Current challenges to get there:– Device limitations – pump imprecision, sensor inaccuracy/unreliability– Biology – complicated– Inter-individual variability – one size fits all possible? Smart algorithms?

• Big developments are happening rapidly!

Artificial Pancreas• First step recently approved

• Medtronic 530G Threshold Suspend System– 530G pump– Enlite CGM

• In-clinic data submitted

• Post Approval study: FDA requested Pediatric access in the Post Approval study

Mobile Applications• To facilitate new technologies, mobile platforms are key

– Nearly everyone now carries a cell phone– Enable functions to allow for medical device interaction from that platform

• Challenges include:– Security, hacking – specialized communication protocols essential– Android vs. Apple OS– Mechanisms for verification of software/OS updates and upgrades

• FDA:– Is working closely with industry on requirements/process for market entry, upgrades,

etc. – need to reach the right regulatory touch– Has already cleared/approved many apps in for use with diabetes devices– Published final guidance on Mobile medical Apps – provides more clarity and

transparency (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf)

• Promises to be more convenient for patients

New TechnologiesNeeded Quality of Life Improvements:

• Consolidation of devices (meters, pumps, lancets, cell phones, etc.)

• Easy data interpretation, standard data format and metrics

• Consolidation of software/applications

• Remote upload/data access capabilities (cloud computing)

• Easier/faster download capabilities

• Improved patient interaction with healthcare professionals

• Efforts to better reach Patients• FDA is trying to find ways to increase input from patients so that we can

do a better job of taking the patient perspective when making premarket and postmarket decision.

• The patient portal is an attempt to create better communication with the community

• We get a lot of perspective from working with patients:• Face to face discussions• Conferences• Working with investigators and their patients, etc.

• Grassroots efforts (e.g., #StripSafely campaign): Good Communication is key!

Patient Interaction

What Can You Do?• Report adverse events (to the manufacturer and the FDA) • Comment to the Docket for the draft guidances• Become informed on the facts (from all perspectives)

Questions?

Thank you!

EFFECTIVE PATIENT ADVOCACY

PRESENTEDBY MICHAEL MANGANIELLO

FOUNDING PARTNER, HCM STRATEGISTS

The Power Of Patients

Patient Driven CHANGE Is Possible

Back to BasicsATTENTION

KNOWLEDGE & SOLUTIONS

COMMUNITY

ACCOUNTABILITY

LEADERSHIP

Key Accomplishments

Garnered Political Will to Support Federal Investment in Research and Care

Parallel Track

Accelerated Approval

The Model Works Across Diseases

Right?

Cystic Fibrosis Foundation

KalydecoCF trial showed the drug could improve lung function for a small segment of the CF population (4% or 1,200 kids) with a specific genetic mutation

From CFF’s perspective – 10% improved lung function for 4% was very significant

Developed a strategy to have FDA recognize the benefit for this community

2012The effort worked.

FDA Approved Kalydeco3 months after it was submitted for review

FDA EVENTUALLY UnderstoodWhat Patients KNEW from the START

There Was Significant Benefit!

Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Sarepta Therapeutics - positive results in clinical study of 12 boys

FDA expresses skepticism

Parents and families mount aggressive FDA campaign

5 months later

FDA details a potential path forward for the drug and indicated willingness to consider it for accelerated approval

Back to BasicsATTENTION

KNOWLEDGE & SOLUTIONS

COMMUNITY

ACCOUNTABILITY

LEADERSHIP

Thank YouPresented by: Michael ManganielloEmail: michael_manganiello@hcmstrategists.comPhone: 202.547.2222Link For Back to Basics: http://hcmstrategists.com/wp-content/themes/hcmstrategists/docs/Back2Basics_HIV_AIDSAdvocacy.pdf

Any First Timers?

I.O.U. Pay it forward.

YOUPay it forward.

TELLYOUR STORY

Slide 108

Understanding Diabetes: Knowledge and Solutions

Kelly Close and Adam BrowndiaTribe (www.diaTribe.org)Close Concerns (www.closeconcerns.com)

Diabetes Advocates’ Master LabCWD Friends for Life 2014

Slide 109

About Us: Kelly and Adam

years with diabetes: 38

years on a pump: 29

years on CGM: 10

infusion sets changed: 3,528

test strips used: 69,350

Slide 110

About Us: Kelly and Adam

Years we want to live:

LOTS!

Slide 111

About Us

“I founded Close Concerns to make everyone smarter about diabetes and obesity.”

Slide 112

Outline

• What is A1c not telling us? – Why a 7% ≠ 7%!

• Bridging the Gap – Type 1 AND Type 2 Diabetes

• Advocacy – Successful Examples and Upcoming Opportunities

Slide 113

Outline

• What is A1c not telling us? – Why a 7% ≠ 7%!

• Bridging the Gap – Type 1 AND Type 2 Diabetes

• Advocacy – Successful Examples and Upcoming Opportunities

Slide 114

ADA’s “Estimated Average Glucose”

Slide 115

“Translating the A1C Assay Into Estimated Average Glucose Values” – Nathan et al., 2008

Source: Dr. David Nathan et al., Diabetes Care 2008

Slide 116

A1c does not tell the full story!

An A1c of 7% = average blood glucose of 154 mg/dl

Range Example 1

< 70 mg/dl 8%70-180 mg/dl 63%> 180 mg/dl 29%

Approximate A1c 7.0%

Example 2

24%18%58%

7.0%

Example 3

-100%

-

7.0%

But time in range – and thus ‘quality of A1c’ – can be dramatically different!

Source: Dr. David Nathan et al., Diabetes Care 2008

Slide 117

Example 1 – A1c of 7%

In-Range63%

Hyperglycemia29%

Hypoglycemia8%

Slide 118

Example 2 – A1c of 7%

In-Range18%

Hyper-glycemia

58%

Hypo-glycemia

24%

Slide 119

Example 3 – A1c of 7%

In-Range100%

Slide 120

FDA’s 2008 Draft Guidance on Diabetes Drug Development

• “For the purposes of drug approval and labeling, the final demonstration of efficacy should be based on reduction in A1c, which will support an indication of glycemic control.”– But what about:

• Hypoglycemia?• Weight?• Ease of use?• Taking less insulin?• And scads of other things?

Slide 121

Is the tide changing?

Slide 122

Is the tide changing?

Slide 123

But there is more work to be done!

• Afrezza label does not mention the hypoglycemia or weight benefits in type 1 diabetes

• CGM is still rarely used in drug trials

• Industry may not take time-in-range seriously until it’s incorporated/emphasized in FDA drug guidance

• Payers need to understand the patient perspective – A1c is not everything!

Slide 124

We Need Therapies That Increase Time in Zone

Slide 125

Outline

• What is A1c not telling us? – Why a 7% ≠ 7%!

• Bridging the Gap – Type 1 AND Type 2 Diabetes

• Advocacy – Successful Examples and Upcoming Opportunities

Slide 126

Common conceptions about the different types of diabetes

Type 1• No insulin

production• Often insulin

sensitive• Younger• Thin• Genetic• Treatment: insulin

Type 2• Some insulin

production• Insulin resistance• Older• Obesity• Lifestyle• Treatments: diet,

exercise, pills

Slide 127

But there are so many commonalities...!

Diabetes• Problems with

glucose& insulin metabolism

• Absence/presence of insulin production

• Glucagon dysregulated

• Insulin resistance• Glycemic variability• Genetics• Lifestyle• Drugs• Glucose monitoring• Hypoglycemia• Complications• Stigma/Burden/

Stress• Impact on family

Type 1 Type 2

Slide 128

Implications of this dichotomy

“We have an uphill battle to reeducate people. Many think that type 1 diabetes is insulin-only, and these drugs are for type 2s only. I think we have to figure out how to get ADA, JDRF, ad agencies, and the Helmsley Charitable Trust funding some of this. It’s now coming together – people with type 1 may benefit from type 2 drugs, and people with type 2 should start insulin earlier.”

– Dana Ball, Co-Founder, T1D Exchange; former Director, Helmsley Charitable Trust’s T1D Program

Slide 129

Can type 1s benefit from type 2 drugs?• Yes!

– Metformin– GLP-1 agonists– SGLT-2 inhibitors

Slide 130

Metformin for type 1 diabetes

Slide 131

GLP-1 Agonists for type 1 diabetes

Slide 132

SGLT-1/2 inhibitor data in Type 1

• Lexicon’s LX4211 reduced bolus insulin by 32% over 4 weeks

• Reduced A1c by 0.55%• Less hyperglycemia (CGM > 180 mg/dl): from 36% to

25%• More time in range (70-180mg/dl): from 56% to 68%• No extra hypoglycemia• Less glycemic variability by multiple measures• Weight reduction of 1.7 kg

Phase 3 planning ongoing for type 1 diabetes; awaiting phase 3 partnership for type 2 diabetes

Slide 133

Can type 2s benefit from type 1 treatment approaches?

• Yes!– Earlier, more frequent use of insulin– Treat to success– Therapeutic targeting using CGM– More convenient insulin delivery– Maybe even automated insulin delivery

Slide 134

Earlier, more frequent use of insulin in type 2 diabetes

Source: Ali et al., NEJM 2013

2003-2006 2007-20100%

10%20%30%40%50%60%70%80%90%

100%

57%52%

A1c under 7%

Perc

enta

ge o

f Pati

ents

2003-2006 2007-2010

13% 13%

A1c over 9%

Less than 29% of patients are on

insulin!

Slide 135

CGM for Type 2 Diabetes

Source: Vigersky et al., Diabetes Care, 2012

Slide 136

Insulin Pump Therapy for Type 2 Diabetes

Medtronic’s OpT2mise trial – pumps vs. MDI in T2D• Better A1c reduction: -1.1% (pumps) vs. -0.4%

(MDI)• Less insulin: 20% lower daily dose with pump

therapy • No severe hypoglycemia, no difference in weight

gain

Slide 137

Artificial Pancreas for Type 2 Diabetes

Slide 138

Other Mutually Beneficial Areas

• Biological research into causes and mechanisms of diabetes– Beta/alpha cell function– Insulin resistance– Diet– Genetics/Environment

• Complications research and therapies• Research/therapies for reducing glycemic

variability and hypoglycemia• Diabetes-friendly changes to the food

environment, city designs

Slide 139

Key Takeaway

Advances in type 2 diabetes benefit those with type 1 diabetes. Advances in type 1

diabetes benefit those with type 2 diabetes.

We are all on the same team:Better lives for people with diabetes!

Slide 140

Outline

• What is A1c not telling us? – Why a 7% ≠ 7%!

• Bridging the Gap – Type 1 AND Type 2 Diabetes

• Advocacy – Successful Examples and Upcoming Opportunities

Slide 141

Example #1: JDRF – CGM and AP Guidance

Slide 142

Example #2: StripSafely

Slide 143

Example #3: Afrezza Open Public Hearing

Slide 144

Upcoming Advocacy Opportunities

Liraglutide 3.0 mg for ObesitySeptember 11, 2014

Washington, DC

Slide 145

Upcoming Advocacy Opportunities

AACE Advocacy MeetingSeptember 12, 2014

Washington, DC

Slide 146

Upcoming Advocacy Opportunities

AACE Consensus Conference on Blood Glucose MonitoringSeptember 29, 2014

Washington, DC

Slide 147

Upcoming Advocacy Opportunities

FDA Virtual Town Hall Meeting on Diabetes November 3, 2014

• “Our goal for this meeting is both to inform the diabetes community of what is already being done as well as hear from them about the issues we have yet to address.”

• Drug + Device Divisions will jointly participate

Slide 148

Advocating with our healthcare providers as well!

• Personal responsibility for us and …• Advocating responsibility for HCPs• Avoiding the treat to failure model• Individualizing therapy• Better feedback loops

Slide 149

Individualize therapy! There is no one-size-fits-all approach… - www.diaTribe.org/patientguide

Slide 150

FAIL!

Avoid the Treat to Failure Model

Slide 151

Aim for better, faster, tighter feedback loops

Measure

Analyze

Make Changes

Live Happier/ Healthier

LifeImprove

Slide 152

Concluding Thoughts

• A1c is not everything – 7% is not the same as 7%

• There many similarities between T1D and T2D – advances in each benefit the other

• Many upcoming opportunities for advocacy with the FDA, professional organizations, and with our own healthcare providers

• The voice of the patient must always stay at the center of therapy development, approval, and reimbursement.

Slide 153

THANK YOU!kelly.close@diaTribe.org

adam.brown@diaTribe.org

www.diaTribe.org+1 415 241 9500

The Art and Power of InfluenceOne Advocate’s Advice

Rebecca Wilkes Killion

Patient History

• Adult Onset: 38 years old

• 1st Diagnosis: Type 2

• 2001: Near Fatal DKA

• 2nd Diagnosis: Type 1

FDA Patient Representative

• Appointed in 1999

• First Wave• Member of the Endocrinologic and Metabolic

Drugs Advisory Committee

• First Meeting: Withdrawal of Troglitazone

Epiphany

5 Tips for Making an Impact

1. Membership Has its Privileges

2. Stand in Your Own Truth

3. Cut to the Chase

4. Visual Aids

5. Own Your Space

783% increase

783% increase

783% increase

783% increase

“There is no such thing as small change.”

- Meri Schumacher